Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
28 hedge funds and large institutions have $225M invested in Sinovac Biotech, Ltd in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 0 closing their positions.
4% more funds holding
Funds holding: 27 → 28 (+1)
0% more capital invested
Capital invested by funds: $225M → $225M (+$329K)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Aprio Wealth Management
Atlanta,
Georgia
|
+$284K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$45.3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $184M | – | – | – |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $38.2M | – | – | – |
|
|
NAH
3
Neumann Advisory (HK)
Central,
Hong Kong
| $2.04M | – | – | – |
|
|
AWM
4
Aprio Wealth Management
Atlanta,
Georgia
| $284K | +$284K | +439 | New |
|
5
Wells Fargo
San Francisco,
California
| $109K | – | – | – |
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $106K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $59.7K | +$45.3K | +7,000 | +315% |
|
8
Morgan Stanley
New York
| $59.2K | – | – | – |
|
|
HI
9
Horizon Investments
Charlotte,
North Carolina
| $336 | – | – | – |
|
SVA Hedge Fund Activity: Q4 2025 in Review
28 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q4 2025, worth a combined $225M — up 0.15% from $225M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SVA positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Aprio Wealth Management, opening a new position worth an estimated $284K.
- 28 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q4 2025, up from 27 in Q3 2025.
- Funds reported $225M of Sinovac Biotech, Ltd stock for Q4 2025, up 0.15% quarter-over-quarter.
- 1 fund opened new Sinovac Biotech, Ltd positions in Q4 2025 and 0 closed out, a net change of +1 holder.
- The largest Sinovac Biotech, Ltd buyer in Q4 2025 was Aprio Wealth Management, an estimated $284K added.
Based on aggregated 13F filings for Q4 2025.